{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:05:07Z","timestamp":1760551507350,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10072-021-05546-y","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T15:02:40Z","timestamp":1628953360000},"page":"4837-4838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Severe lymphopenia switching from Fingolimod to Siponimod"],"prefix":"10.1007","volume":"42","author":[{"given":"Maddalena","family":"Sparaco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Miele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"5546_CR1","unstructured":"EMA, Mayzent (2020)\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent. Accessed 11 Dec 2019"},{"key":"5546_CR2","unstructured":"FDA. Mayzent (siponimod) label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209884s000lbl.pdf. Initial U.S. Approval: 2019"},{"issue":"10127","key":"5546_CR3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Clinical EXPAND, Investigators. et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263\u20131273","journal-title":"Lancet"},{"key":"5546_CR4","unstructured":"FDA. Gilenya (fingolimod) label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022527s008lbl.pdf. Initial U.S. Approval: 2010"},{"issue":"2","key":"5546_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14656566.2018.1551363","volume":"20","author":"L Dumitrescu","year":"2019","unstructured":"Dumitrescu L, Constantinescu CS, Tanasescu R (2019) Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opin Pharmacother 20(2):143\u2013150","journal-title":"Expert Opin Pharmacother"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05546-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T13:35:45Z","timestamp":1634391345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05546-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5546"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05546-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"5 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethical Commitee of University of Campania Luigi Vanvitelli approved the case report in anonymized form (protocol number 0010207\/i.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient signed an informed consent to publish clinical data in anonimous form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}